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The 75ArC Substitution in the 5′ UTR of the
Wilson Disease Gene Is a Sequence Polymorphism in
the Mediterranean Population
To the Editor:
In their haplotype and mutation analysis of Wilson dis-
ease (WD) in Japanese patients, Nanji et al. (1997) re-
port an ArC substitution at position 75 in the 5′ UTR
of the WD gene, found in 1/42 WD chromosomes in-
vestigated. The authors considered this substitution to
be a disease-causing mutation, and they postulated that
the mutation adversely affects WD-gene expression, ei-
ther by abolishing ribosome binding or by interfering
negatively with transcriptional factor(s)–DNA binding.
However, Nanji et al. (1997) did not report screening
for the presence of the ArC mutation in normal chro-
mosomes, to exclude the possibility that this mutation
is a simple polymorphism.
Of 228 WD chromosomes analyzed in our study of
WD in Mediterranean populations, we found the
75ArC substitution in 23 WD chromosomes that
carry an unquestionable disease-causing mutation, as
well as in 16 WD chromosomes in which the mutation
has not yet been defined. The ArC substitution at po-
sition 75 was also detected in 15 (28%) of 54 normal
chromosomes from the same Mediterranean population.
These data clearly indicate that75ArC is a sequence
polymorphism that most likely does not affect the func-
tion of the WD gene. We previously reported the same
ArC substitution in the 5′ UTR (Figus et al. 1995); how-
ever, because of erroneous numbering of the nucleotide
sequence in the sequence ladder, we incorrectly indicated
its position as 74 instead of 75.
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Reply to Loudianos et al.
To the Editor:
We appreciate receiving additional information on the
ArC substitution at position 75 in the 5′ UTR of the
Wilson disease gene. When we reported this substitution
(Nanji et al. 1997), we were careful to indicate that it
was in the “putative promoter” region and that it might
be associated with the disease. We pointed out that direct
testing of the effect of the mutation on expression would
be required to confirm the nature of the mutation. We
described the results of the analysis of 21 normal chro-
mosomes from a Japanese group, which is the same eth-
nic group as that of the patient. These normal-chro-
mosome results were obtained from the analysis of the
normal chromosomes in the heterozygous parents of the
patients. None of the putative promoter mutations were
identified in the normal sample. We did report, in table
3 of our previous study (Nanji et al. 1997), some alter-
ations that we felt were definitely polymorphisms. Ap-
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parently, the ArC substitution is more common in the
normal Mediterranean population. We had missed this
because of the error in the study by Figus et al. (1995),
as is noted in the letter by Loudianos et al. (1998 [in
this issue]). Promoter studies are currently in progress
to determine the nature of the mutations reported by us.
MANOJ S. NANJI AND DIANE W. COX
Department of Medical Genetics
University of Alberta
Edmonton
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Reply to Burghes
To the Editor:
In his recent editorial entitled “When Is a Deletion Not
a Deletion? When It Is Converted” Burghes (1997) cor-
rectly ascribes the cause of spinal muscular atrophy
(SMA) to the loss or mutation of the telomeric copy of
the SMN (survival motor neuron) gene. The reduction
in SMN protein, as Burghes recognizes, most likely leads
to motor-neuron death, by unknown mechanisms
(Coovert et al. 1997; Lefebvre et al. 1997). He also out-
lines the probable role of centromeric copies of SMN in
the modulation of disease severity (Campbell et al. 1997;
Velasco et al. 1996; McAndrew et al. 1997). However,
concerning a second SMA candidate gene, known as
NAIP (neuronal apoptosis–inhibitory protein), Burghes
states that “it appears likely that the deletion of NAIP
marks the extent of the [genomic] deletion and that dif-
ferent forms of SMNcen modify the SMA phenotype,”
thereby rejecting a role for NAIP in SMA pathogenesis.
On this final point we strongly disagree. During the
past 2 years, our group, our collaborators, and other
laboratories have shown that NAIP could be involved
in SMA pathogenesis in several ways. First, in most pop-
ulations the NAIP gene is deleted in the majority of type
I SMA individuals. In some type I SMA populations, the
deletion of SMNtel extends to NAIP in 180% of affected
chromosomes (Morrison 1996; Samilchuk et al. 1996;
Velasco et al. 1996). Second, in the CNS, NAIP is ex-
pressed in at least eight distinct neuronal populations,
including the motor neurons, all of which are affected
in type I SMA (Towfighi et al. 1985; Murayama et al.
1991; Peress et al. 1986; Xu et al. 1997b). A number
of NAIP-positive neuronal types (e.g., cholinergic neu-
rons of the striatum), when subjected to ischemia, dem-
onstrate both a significant increase in NAIP levels (Xu
et al. 1997a) as well as a marked resistance to apoptotic
death. Third, NAIP exerts an antiapoptotic effect in cul-
tured cells (Liston et al. 1996) and affords hippocampal
neuroprotection in vivo when overexpressed from a
transgene (Xu et al. 1997a).
In view of these data, we find the assertion surprising
that the NAIP gene serves merely as a marker of ge-
nomic-DNA deletion size. Clearly, formal proof of NAIP
involvement in SMA pathogenesis must await further
analysis (e.g., exacerbation of an SMA phenotype in
SMN-deficient mice when expression of NAIP is com-
promised). However, we feel that it is likely that motor
neurons from SMA individuals with deletions of both
NAIP and SMNtel are prone to apoptosis. As a result,
the cells are less able to withstand the stress of SMN
depletion and die earlier than they would otherwise, re-
sulting in a more severe form of SMA.
ALEX E. MACKENZIE
Division of Genetics
Children’s Hospital of Eastern Ontario
University of Ottawa
Ottawa
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